. 2019 Sep 10;18(5):4629–4638. doi: 10.3892/ol.2019.10842

Table IV.

Associations of SNPs in selected genes and PFS in patients with advanced gastric cancer.

					Univariate analysis		Multivariate analysis

SNP	Outcome	mPFS, months	Model	Log-rank P-value	HR (95% CI)	P-value	HR (95% CI)^a	P-value^a
KDR rs7692791	PFS		General	0.032		0.020		0.012
		4.2	CC	0.099^b	1.926 (0.859–4.319)	0.112	2.053 (0.855–4.929)	0.107
		5.0	CT	0.018^b	1.829 (1.091–3.066)	0.022	1.969 (1.150–3.369)	0.013
		6.0	TT		Reference		Reference
			Dominant	0.009		0.010		0.006
		6.0	TT		Reference		Reference
		5.0	CC+CT		1.892 (1.156–3.098)	0.011	1.982 (1.196–3.284)	0.008
KDR rs1870377	PFS		General	0.030		0.017		0.127
		4.0	AA	0.005^b	3.221 (1.356–7.651)	0.008	2.892 (0.987–8.474)	0.053
		5.5	AT	0.015^b	2.545 (1.159–5.589)	0.020	1.778 (0.724–4.366)	0.209
		10.0	TT		Reference		Reference
			Dominant	0.008		0.009		0.051
		10.0	TT		Reference		Reference
		4.5	AA+AT		2.618 (1.235–5.550)	0.012	1.970 (0.861–4.503)	0.108
NRP-1 rs2065364	PFS		Recessive	0.015		0.017		0.004
		8.0	AA		Reference		Reference
		4.5	AG+GG		2.896 (1.159–7.237)	0.023	3.905 (1.485–10.268)	0.006

Adjusted for age, sex, N stage, TNM stage, platinum included or not and differentiation.

Bonferroni-adjusted P-value=0.05/2, so P<0.025 was considered statistically significant. CI, confidence interval; HR, hazard ratio; KDR, kinase insert domain receptor; NRP-1, neuropilin-1; PFS, progression-free survival; mPFS, median progression-free survival; SNP, single nucleotide polymorphism.